Volitionrx limited announces first quarter 2021 financial results and business update

Secured strongest-ever balance sheet with approximately $33.1 million in cash strengthened the company's leadership team to drive commercial focus expanded the company's intellectual property portfolio initiated production of product components at scale at the company's silver one facility published three clinical papers continued focus on product launches and licensing in both the human and veterinary spaces austin, texas, may 11, 2021 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition") today announced financial results and a business update for the first quarter ended march 31, 2021. volition management will host a conference call tomorrow, may 12 at 8:00 a.m.
VNRX Ratings Summary
VNRX Quant Ranking